Viatris Join Forces with Lexicon Pharmaceuticals to Commercialize Sotagliflozin Across all Markets Outside of the US and EU
Shots:
- Viatris and Lexicon Pharmaceuticals have signed an exclusive licensing agreement as per which Viatris secures rights of sotagliflozin outside the US & EU
- Lexicon will supply sotagliflozin for clinical & commercial purposes and will receive $25M upfront, regulatory & sales milestones plus low-double-digit to upper-teens tiered royalties based on net sales. Viatris will handle regulatory & commercialization activities; plans to account for the transaction as an asset acquisition, with the upfront payment expensed as in-process R&D
- The partnership will leverage Viatris' cardiovascular expertise and Global Healthcare Gateway, providing partners access to global markets and patients
Ref: Viatris | Image: Viatris and Lexicon Pharmaceuticals
Related News: Lexicon’s Inpefa (sotagliflozin) Receives the US FDA’s Approval for the Treatment of Heart Failure
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
